While PET imaging with radiolabeled antibodies has shown promise in GPC3-positive HCC [38,39,40], it is costly and carries the risk of radiation exposure; additionally, PET imaging probes face higher regulatory hurdles [41]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.